New Diabetes Drug Shows Effectiveness

Tuesday, 16 Apr 2013 12:15 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink
Eli Lilly and Co said two additional late-stage studies testing its experimental diabetes drug dulaglutide met the main goal of reducing hemoglobin A1c levels, a measure of blood sugar.
 
Along with positive results from three other late-stage trials announced in October, the data will support a marketing application for dulaglutide, Lilly said in a statement.
 
In the study named AWARD 2, the company said a 1.5 mg dose of its drug proved superior to Sanofi's Lantus, at 52 weeks in Type 2 diabetes patients, who are already on two other diabetes drugs, metformin and glimeperide.
 
Dulaglutide also trumped insulin lispro, in combination with Lantus, at 26 weeks of treatment in a study dubbed as AWARD 4, Lilly said.
 
The company said the most frequently reported adverse events were gastrointestinal.
 
In October, Lilly reported positive results of the other three studies in which dulaglutide was compared with other diabetes medications.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Health Officials Vow to Stop Ebola From Spreading in US

Tuesday, 30 Sep 2014 20:57 PM

A man who flew from Liberia to Texas has become the first patient infected with the deadly Ebola virus to be diagnosed i . . .

Spacing Between Sibling Births Linked to Autism Risk

Tuesday, 30 Sep 2014 19:13 PM

Children conceived either less than one year or more than five years after the birth of a sibling could be at increased  . . .

Light at Night May Hamper Breast Cancer Treatment: Study

Tuesday, 30 Sep 2014 19:08 PM

A study in rats hints that exposure to dim light at night may make human breast cancer tumors resistant to the chemother . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved